Drug Detail:Eflapegrastim (Eflapegrastim [ ef-la-peg-ra-stim ])
Drug Class: Colony stimulating factors
Usual Adult Dose for Neutropenia Associated with Chemotherapy
Usual dose: 13.2 mg subcutaneously once per chemotherapy cycle
Comments:
- Dose should be given at least 24 hours after cytotoxic chemotherapy.
- This drug should not be administered within the period from 14 days before to 24 hours after administration of cytotoxic chemotherapy.
- This drug is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Use: To decrease the incidence of infection, manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of neutropenia and fever.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Adjustments
Therapeutic drug monitoring range: Leukocyte count 100 x 10(9)/L or greater: Treatment should be stopped.
Precautions
CONTRAINDICATIONS: Patients with a history of serious allergic reactions to eflapegrastim, pegfilgrastim, or filgrastim products.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug should be administered subcutaneously via a single-dose prefilled syringe by a healthcare professional.
- Prior to the administration, remove the drug from refrigerator and allow it to reach room temperature.
- Visually examine for any particulate matter or discoloration prior to administration.
- Administer the entire contents of the prefilled syringe.
- In case of missed dose, contact health care professional.
Storage requirements:
- Store refrigerated at 36F to 46F (2C to 8C) and do not freeze; protect from light.
- Discard syringes stored at room temperature for more than 12 hours or if frozen.
- Do not shake.
Reconstitution/preparation techniques:
- This drug comes in prefilled syringe and is only intended to deliver the entire contents of the syringe (13.2 mg/0.6 mL) for direct administration.
Monitoring:
- HEMATOLOGIC: Complete blood count should be monitored during the treatment
- RENAL: Urinalysis
Patient advice:
- Advise the patient to read the FDA-approved patient labeling (Patient Information).
- Patients should be informed about the associated and potential risks with this drug.
- Contact health care professional in case of any questions.
